AC Immune SA (ACIU) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1114531,
    "name": "AC Immune SA",
    "stock_name": "AC Immune SA",
    "full_name": "AC Immune SA",
    "name_url": "stocks-analysis/ac-immune-sa",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.88",
    "chg": 0.11,
    "chgp": "3.97%",
    "dir": 1,
    "prev_price": "2.77",
    "mcapval": "231.36",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "CH0329023102",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "275.86 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ac-immune-sa-1114531-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "AC Immune SA Hits New 52-Week High of $4.00, Marking Major Milestone",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ac-immune-sa-hits-new-52-week-high-of-400-marking-major-milestone-3659116",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ACImmuneSA_priceRelatedfactors_3659116.png",
        "date": "2025-10-30 18:31:21",
        "description": "AC Immune SA achieved a new 52-week high of USD 4.00 on October 29, 2025, marking a notable milestone for the microcap company in the Pharmaceuticals & Biotechnology sector. Despite this, the company's one-year performance shows a decline, and it remains loss-making with a negative return on equity."
      },
      {
        "title": "AC Immune SA Hits New 52-Week High of USD 3.99",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ac-immune-sa-hits-new-52-week-high-of-usd-399-3595613",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ACImmuneSA_priceRelatedfactors_3595613.png",
        "date": "2025-10-06 17:31:32",
        "description": "AC Immune SA achieved a new 52-week high of USD 3.99 on October 3, 2025, marking a significant milestone for the microcap biotechnology company. Despite this achievement, the company's one-year performance shows a decline, reflecting challenges in its financial metrics and overall market conditions."
      },
      {
        "title": "AC Immune Forms Golden Cross, Signaling Potential Bullish Breakout Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ac-immune-forms-golden-cross-signaling-potential-bullish-breakout-ahead-3559445",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/ACImmuneSA_goldencross_3559445.png",
        "date": "2025-09-23 15:40:04",
        "description": "AC Immune SA has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock rose 3.27% today, outperforming the S&P 500. Despite a challenging year, recent bullish indicators suggest a possible turnaround, prompting increased interest from investors as they monitor future developments."
      },
      {
        "title": "Is AC Immune SA technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ac-immune-sa-technically-bullish-or-bearish-3546412",
        "imagepath": "",
        "date": "2025-09-20 19:31:56",
        "description": "As of 4 June 2025, the technical trend for AC Immune SA has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish sentiment, while the weekly MACD and Bollinger Bands show bullish signals. However, the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The Dow Theory indicates a mildly bullish stance on both weekly and monthly charts, while the On-Balance Volume (OBV) also reflects a mildly bullish trend.\n\nIn terms of performance, AC Immune has outperformed the S&P 500 over the past week and month, with returns of 5.88% and 17.21% respectively, but it has significantly underperformed over longer periods, including a -30.58% return over the past year compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is AC Immune SA overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ac-immune-sa-overvalued-or-undervalued-3542991",
        "imagepath": "",
        "date": "2025-09-20 18:07:53",
        "description": "As of 14 March 2024, the valuation grade for AC Immune SA has moved from does not qualify to risky, indicating a shift in perception towards the company's financial health. The company appears to be overvalued, given its negative earnings and significant losses reflected in key ratios. The price-to-book value stands at 2.00, while the EV to EBITDA and EV to EBIT ratios are both negative at -0.93 and -0.89, respectively, highlighting the challenges in generating positive cash flows.\n\nIn comparison with peers, AC Immune SA's P/E ratio is not applicable due to its loss-making status, while Lexicon Pharmaceuticals has a P/E of -3.53 and Vanda Pharmaceuticals has a P/E of -4.02, indicating that AC Immune is not alone in facing valuation challenges within this sector. Over the past year, AC Immune SA has underperformed significantly, with a return of -30.58% compared to the S&P 500's 17.14%, reinforcing the notio..."
      }
    ],
    "total": 10,
    "sid": "1114531",
    "stock_news_url": "https://www.marketsmojo.com/news/ac-immune-sa-1114531"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

AC Immune SA Hits New 52-Week High of $4.00, Marking Major Milestone

2025-10-30 18:31:21

AC Immune SA achieved a new 52-week high of USD 4.00 on October 29, 2025, marking a notable milestone for the microcap company in the Pharmaceuticals & Biotechnology sector. Despite this, the company's one-year performance shows a decline, and it remains loss-making with a negative return on equity.

AC Immune SA Hits New 52-Week High of USD 3.99

2025-10-06 17:31:32

AC Immune SA achieved a new 52-week high of USD 3.99 on October 3, 2025, marking a significant milestone for the microcap biotechnology company. Despite this achievement, the company's one-year performance shows a decline, reflecting challenges in its financial metrics and overall market conditions.

AC Immune Forms Golden Cross, Signaling Potential Bullish Breakout Ahead

2025-09-23 15:40:04

AC Immune SA has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock rose 3.27% today, outperforming the S&P 500. Despite a challenging year, recent bullish indicators suggest a possible turnaround, prompting increased interest from investors as they monitor future developments.

Is AC Immune SA technically bullish or bearish?

2025-09-20 19:31:56

As of 4 June 2025, the technical trend for AC Immune SA has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish sentiment, while the weekly MACD and Bollinger Bands show bullish signals. However, the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The Dow Theory indicates a mildly bullish stance on both weekly and monthly charts, while the On-Balance Volume (OBV) also reflects a mildly bullish trend. In terms of performance, AC Immune has outperformed the S&P 500 over the past week and month, with returns of 5.88% and 17.21% respectively, but it has significantly underperformed over longer periods, including a -30.58% return over the past year compared to the S&P 500's 17.14%....

Is AC Immune SA overvalued or undervalued?

2025-09-20 18:07:53

As of 14 March 2024, the valuation grade for AC Immune SA has moved from does not qualify to risky, indicating a shift in perception towards the company's financial health. The company appears to be overvalued, given its negative earnings and significant losses reflected in key ratios. The price-to-book value stands at 2.00, while the EV to EBITDA and EV to EBIT ratios are both negative at -0.93 and -0.89, respectively, highlighting the challenges in generating positive cash flows. In comparison with peers, AC Immune SA's P/E ratio is not applicable due to its loss-making status, while Lexicon Pharmaceuticals has a P/E of -3.53 and Vanda Pharmaceuticals has a P/E of -4.02, indicating that AC Immune is not alone in facing valuation challenges within this sector. Over the past year, AC Immune SA has underperformed significantly, with a return of -30.58% compared to the S&P 500's 17.14%, reinforcing the notio...

View All News